KR102311761B1 - 항-Siglec-8 항체 및 그의 사용 방법 - Google Patents

항-Siglec-8 항체 및 그의 사용 방법 Download PDF

Info

Publication number
KR102311761B1
KR102311761B1 KR1020167018130A KR20167018130A KR102311761B1 KR 102311761 B1 KR102311761 B1 KR 102311761B1 KR 1020167018130 A KR1020167018130 A KR 1020167018130A KR 20167018130 A KR20167018130 A KR 20167018130A KR 102311761 B1 KR102311761 B1 KR 102311761B1
Authority
KR
South Korea
Prior art keywords
antibody
seq
amino acid
delete delete
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167018130A
Other languages
English (en)
Korean (ko)
Other versions
KR20160095113A (ko
Inventor
크리스토퍼 알. 베빙턴
러스텀 파라하티
캐롤리나 리타 수자 페르난데스
데이비드 존 매튜
네나드 토마세빅
제이슨 윌리암스
존 렁
Original Assignee
알라코스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알라코스 인크. filed Critical 알라코스 인크.
Priority to KR1020217032002A priority Critical patent/KR20210125114A/ko
Publication of KR20160095113A publication Critical patent/KR20160095113A/ko
Application granted granted Critical
Publication of KR102311761B1 publication Critical patent/KR102311761B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020167018130A 2013-12-09 2014-12-09 항-Siglec-8 항체 및 그의 사용 방법 Active KR102311761B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217032002A KR20210125114A (ko) 2013-12-09 2014-12-09 항-Siglec-8 항체 및 그의 사용 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361913891P 2013-12-09 2013-12-09
US61/913,891 2013-12-09
PCT/US2014/069409 WO2015089117A1 (en) 2013-12-09 2014-12-09 Anti-siglec-8 antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217032002A Division KR20210125114A (ko) 2013-12-09 2014-12-09 항-Siglec-8 항체 및 그의 사용 방법

Publications (2)

Publication Number Publication Date
KR20160095113A KR20160095113A (ko) 2016-08-10
KR102311761B1 true KR102311761B1 (ko) 2021-10-13

Family

ID=53371783

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167018130A Active KR102311761B1 (ko) 2013-12-09 2014-12-09 항-Siglec-8 항체 및 그의 사용 방법
KR1020217032002A Ceased KR20210125114A (ko) 2013-12-09 2014-12-09 항-Siglec-8 항체 및 그의 사용 방법
KR1020237021876A Ceased KR20230107382A (ko) 2013-12-09 2014-12-09 항-Siglec-8 항체 및 그의 사용 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217032002A Ceased KR20210125114A (ko) 2013-12-09 2014-12-09 항-Siglec-8 항체 및 그의 사용 방법
KR1020237021876A Ceased KR20230107382A (ko) 2013-12-09 2014-12-09 항-Siglec-8 항체 및 그의 사용 방법

Country Status (24)

Country Link
US (4) US9546215B2 (https=)
EP (2) EP3611191A1 (https=)
JP (4) JP6549143B2 (https=)
KR (3) KR102311761B1 (https=)
CN (3) CN105916519B (https=)
AU (2) AU2014363944B2 (https=)
BR (1) BR112016013109B1 (https=)
CA (1) CA2930886C (https=)
CY (1) CY1122329T1 (https=)
DK (1) DK3079719T3 (https=)
ES (1) ES2758508T3 (https=)
HR (1) HRP20192052T1 (https=)
HU (1) HUE047283T2 (https=)
IL (3) IL298470A (https=)
LT (1) LT3079719T (https=)
NZ (1) NZ720769A (https=)
PL (1) PL3079719T3 (https=)
PT (1) PT3079719T (https=)
RS (1) RS59567B1 (https=)
SG (2) SG11201604632PA (https=)
SI (1) SI3079719T1 (https=)
SM (1) SMT201900714T1 (https=)
WO (1) WO2015089117A1 (https=)
ZA (1) ZA201603435B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2939931C (en) * 2014-02-28 2025-04-22 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SIGLEC8
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US10774145B2 (en) 2015-06-17 2020-09-15 Allakos Inc. Methods and compositions for treating fibrotic diseases
US10604577B2 (en) * 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018129400A1 (en) * 2017-01-06 2018-07-12 Allakos Inc. Methods and compositions for treating chronic obstructive pulmonary disorder
EP3618872A4 (en) * 2017-05-05 2021-06-30 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY STOMACH AND INTESTINAL DISEASES
KR20200016232A (ko) * 2017-05-05 2020-02-14 알라코스 인크. 알레르기성 안구 질환을 치료하기 위한 방법 및 조성물
JP2021508719A (ja) 2017-12-29 2021-03-11 コーネル・ユニバーシティーＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ 好酸球性障害のための遺伝子療法
BR112020022236A2 (pt) * 2018-05-04 2021-02-02 Allakos Inc. métodos e composições para tratamento de urticária crônica
WO2020168271A1 (en) * 2019-02-15 2020-08-20 Allakos Inc. Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis
CA3149484A1 (en) * 2019-08-02 2021-02-11 Bhupinder Singh Methods of administering anti-siglec-8 antibodies and corticosteroids
EP4048698A4 (en) * 2019-10-24 2023-12-06 Allakos Inc. Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
CN114945592B (zh) * 2019-11-19 2025-09-19 宾夕法尼亚大学董事会 抗-α-突触核蛋白单克隆抗体及其使用方法
US20230210989A1 (en) * 2020-06-03 2023-07-06 Kar Muthumani Monoclonal Antibody Against Human Siglec-9 and Use For Immunotherapy
WO2022061032A1 (en) * 2020-09-17 2022-03-24 Allakos Inc. Methods and compositions for treating viral infection
WO2022215566A1 (ja) * 2021-04-05 2022-10-13 国立大学法人筑波大学 アレルギー性疾患の予防又は治療剤
WO2023215907A1 (en) * 2022-05-06 2023-11-09 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Inhibiting mast cell activation by binding sialic acid-binding immunoglobulin-like lectin-9 (siglec-9)
WO2024043940A1 (en) * 2022-08-25 2024-02-29 Allakos Inc. Methods and compositions for treating atopic dermatitis
WO2024254441A1 (en) * 2023-06-08 2024-12-12 Allakos Inc. Bispecific antibodies to siglec-6 and siglec-8 and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066126A1 (en) 2000-03-07 2001-09-13 Smithkline Beecham Corporation Sialoadhesin factor-2 antibodies
US20030092091A1 (en) * 2000-03-07 2003-05-15 Abrahamson Julie A. Sialoadhesin factor-2 antibodies

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5891693A (en) 1990-01-25 1999-04-06 Alusuisse Holdings A.G. Recombinant DNA methods vectors and host cells
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1997038123A1 (en) 1996-04-05 1997-10-16 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
HUP0600342A3 (en) * 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
JP4832719B2 (ja) 2002-04-09 2011-12-07 協和発酵キリン株式会社 ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
WO2005116088A2 (en) 2004-05-25 2005-12-08 The Johns Hopkins University Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
US20060134098A1 (en) 2004-11-16 2006-06-22 Kalobios, Inc. Immunoglobulin variable region cassette exchange
US8357671B2 (en) 2005-11-10 2013-01-22 James Paulson High affinity Siglec ligands
WO2007056870A1 (en) 2005-11-21 2007-05-24 The Governors Of The University Of Alberta Methods and compositions for pharmacologically controlled targeted immunotherapy
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US8163551B2 (en) 2008-05-02 2012-04-24 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
DK2470671T3 (en) * 2009-08-28 2015-02-09 Regeneron Pharma ANTIKIN- ANTIBODIES BINDING TO MULTIPLE CC chemokines
SG178925A1 (en) 2009-09-22 2012-04-27 Volker Sandig Process for producing molecules containing specialized glycan structures
US8586044B2 (en) 2010-05-28 2013-11-19 Northwestern University Treatment of chronic pelvic pain syndrome
EP2465873A1 (en) 2010-12-16 2012-06-20 Deutsches Rheuma-Forschungszentrum Berlin Eosinophils as a therapeutic target
WO2012120500A2 (en) * 2011-03-06 2012-09-13 Merck Serono S.A. Low fucose cell lines and uses thereof
CA2862925C (en) * 2012-02-10 2020-01-21 University Of Maryland, Baltimore Chemoenzymatic glycoengineering of antibodies and fc fragments thereof
CA2939931C (en) * 2014-02-28 2025-04-22 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SIGLEC8
US10604577B2 (en) * 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
KR20200016232A (ko) * 2017-05-05 2020-02-14 알라코스 인크. 알레르기성 안구 질환을 치료하기 위한 방법 및 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066126A1 (en) 2000-03-07 2001-09-13 Smithkline Beecham Corporation Sialoadhesin factor-2 antibodies
US20030092091A1 (en) * 2000-03-07 2003-05-15 Abrahamson Julie A. Sialoadhesin factor-2 antibodies

Also Published As

Publication number Publication date
CA2930886C (en) 2024-05-21
IL245663B (en) 2021-02-28
RS59567B1 (sr) 2019-12-31
AU2014363944B2 (en) 2020-03-26
CN105916519A (zh) 2016-08-31
HRP20192052T1 (hr) 2020-02-07
JP6963577B2 (ja) 2021-11-10
IL245663A0 (en) 2016-06-30
AU2020204016A1 (en) 2020-07-02
CA2930886A1 (en) 2015-06-18
CN113861293A (zh) 2021-12-31
BR112016013109B1 (pt) 2021-05-11
EP3611191A1 (en) 2020-02-19
DK3079719T3 (da) 2019-11-18
NZ720769A (en) 2022-10-28
SI3079719T1 (sl) 2019-12-31
IL280155A (en) 2021-03-01
JP2020078336A (ja) 2020-05-28
EP3079719B8 (en) 2019-12-04
AU2014363944A1 (en) 2016-06-09
KR20230107382A (ko) 2023-07-14
JP6549143B2 (ja) 2019-07-24
SMT201900714T1 (it) 2020-01-14
JP2017501744A (ja) 2017-01-19
ES2758508T3 (es) 2020-05-05
KR20210125114A (ko) 2021-10-15
US20170209556A1 (en) 2017-07-27
JP2022082715A (ja) 2022-06-02
BR112016013109A2 (pt) 2017-09-26
WO2015089117A1 (en) 2015-06-18
SG11201604632PA (en) 2016-07-28
US9546215B2 (en) 2017-01-17
CY1122329T1 (el) 2021-01-27
CN114044825A (zh) 2022-02-15
PL3079719T3 (pl) 2020-05-18
LT3079719T (lt) 2019-12-10
US20200054723A1 (en) 2020-02-20
JP2019076115A (ja) 2019-05-23
HUE047283T2 (hu) 2020-04-28
US20150203578A1 (en) 2015-07-23
EP3079719A1 (en) 2016-10-19
EP3079719B1 (en) 2019-09-04
EP3079719A4 (en) 2017-08-02
KR20160095113A (ko) 2016-08-10
CN105916519B (zh) 2021-10-22
IL298470A (en) 2023-01-01
SG10201808835QA (en) 2018-11-29
US20220331412A1 (en) 2022-10-20
PT3079719T (pt) 2019-12-05
ZA201603435B (en) 2020-08-26

Similar Documents

Publication Publication Date Title
US20220331412A1 (en) Anti-siglec-8 antibodies and methods of use thereof
JP2017501744A5 (https=)
CA2939931C (en) METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SIGLEC8
US20220162307A1 (en) Methods and compositions for treating allergic ocular diseases
KR20210005245A (ko) 만성 두드러기를 치료하기 위한 방법 및 조성물
HK40020878A (en) Anti-siglec-8 antibodies and methods of use thereof
HK1227743A1 (en) Anti-siglec-8 antibodies and methods of use thereof
HK1227743B (en) Anti-siglec-8 antibodies and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160706

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191209

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201126

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210705

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20211005

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20211005

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20211006

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240919

Start annual number: 4

End annual number: 4